AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a pivotal phase III study titled ‘A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso).’ The study aims to evaluate the efficacy and safety of Volrustomig combined with Carboplatin and Pemetrexed compared to standard treatments in patients with unresectable pleural mesothelioma.
The intervention being tested is Volrustomig (MEDI5752), an experimental drug administered with Carboplatin and Pemetrexed, intended to treat unresectable pleural mesothelioma by potentially improving patient outcomes compared to existing therapies.
This randomized, open-label trial involves approximately 825 participants who will receive either the experimental combination or the investigator’s choice of standard care. The study uses a parallel intervention model with single masking for outcomes assessors, focusing primarily on treatment efficacy.
The study began on October 4, 2023, with an estimated primary completion date in 2025 and the last update submitted on August 27, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The update on this study could influence AstraZeneca’s stock performance positively, as successful outcomes may enhance their oncology portfolio. Investors should also consider the competitive landscape, as other companies are developing treatments for similar conditions.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.